Oxygen Therapeutics: Perfluorocarbons and Blood Substitute Safety

  • Cohn C
  • Cushing M
  • 42

    Readers

    Mendeley users who have this article in their library.
  • 52

    Citations

    Citations of this article.

Abstract

Current demands over the blood supply in developed and developing nations will compound over time. Red cell substitutes have a promising value proposition for transfusion services, because they hold the promise of increasing the availability of blood products and removing donor and contamination safety risks. In this article, the authors note that existing products suffer from critical shortcomings such as vasoactivity; they also point out that substitutes not based on human blood introduce potentially more complex safety hurdles. The authors discuss the attributes of an ideal blood substitute, and the mechanism and current status of perfluorocarbons; they also review the shortcomings of all oxygen therapeutic products in development today. © 2009 Elsevier Inc. All rights reserved.

Author-supplied keywords

  • Blood substitute
  • Hemoglobin-based-oxygen-carrier (HBOC)
  • Perfluorocarbons (PFC)

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Claudia S. Cohn

  • Melissa M. Cushing

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free